

Effectiveness of mRESVIA Against Serious Endpoints related to RSV in Kaiser Permanente Northern California (ERASE-RSV)

First published: 26/03/2026

Last updated: 26/03/2026

Study

Ongoing

Administrative details

EU PAS number

EUPAS1000000946

Study ID

1000000946

DARWIN EU® study

No

Study countries

 United States

Study status

Ongoing

Contact details

Study institution contact

Clinical Trial Disclosure ModernaTX cttd@modernatx.com

Study contact

cttd@modernatx.com

Primary lead investigator

Clinical Trial Disclosure ModernaTX

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 30/10/2024

Study start date

Actual: 01/03/2026

Date of final study report

Planned: 31/01/2029

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only

Other study registration identification numbers and links

mRNA-1345-P919

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Effectiveness study (incl. comparative)

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medicinal product name

MRESVIA

Study drug International non-proprietary name (INN) or common name

RESPIRATORY SYNCYTIAL VIRUS MRNA VACCINE (NUCLEOSIDE MODIFIED)

Anatomical Therapeutic Chemical (ATC) code

(J07BX05) respiratory syncytial virus vaccines

respiratory syncytial virus vaccines

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

Unknown